FTO and acute myeloid leukemia: STM2457 and FB23/FB23-2 were small-molecular inhibitors of m6A regulators, preventing the development of human acute myeloid leukemia cells in vitro by specifically suppressing the activities of METTL3 and FTO, respectively, in recent research (Huang et al., 2019; Yankova et al., 2021).